U.K.’s NICE recommends use of Firmagon in prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The U.K.’s National Institute for Health and Care Excellence recommended the use of Firmagon (degarelix) for men with advanced hormone-dependent prostate cancer with spinal metastases. This announcement follows a three-year review process and NICE’s most recent draft Appraisal Consultation Document published in June 2015, which recommended against the use of Firmagon within its marketing authorization...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login